Finanzen von Aptevo Therapeutics Inc (APVO)APVOAptevo Therapeutics Inc

Evaluating the bottom line, Aptevo Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -446.89%, provide a clear picture of how effectively APVO converts its operational activities into shareholder value.

In the context of the broader market, APVO competes directly with industry leaders such as ELAB and GRI. With a market capitalization of $4.36M, it holds a significant position in the sector. When comparing efficiency, APVO's gross margin of N/A stands against ELAB's 7.99% and GRI's N/A. Such benchmarking helps identify whether Aptevo Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Aptevo has consistently reported negative net income, with the latest figures showing a net loss of $6,356,000 for Q2 2026. The company's EPS has been negative across multiple quarters, indicating ongoing financial struggles.